ASP Isotopes (ASPI) Expected to Announce Earnings on Monday

ASP Isotopes (NASDAQ:ASPI) is expected to be releasing its Q4 2025 results after the market closes on Monday, March 30th. Analysts expect ASP Isotopes to post earnings of ($0.1367) per share and revenue of $2.0310 million for the quarter. Interested persons may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Tuesday, March 31, 2026 at 4:00 PM ET.

ASP Isotopes Stock Down 5.2%

ASPI stock opened at $4.37 on Friday. The stock’s 50 day simple moving average is $5.78 and its 200 day simple moving average is $7.26. The company has a market cap of $484.37 million, a P/E ratio of -3.36 and a beta of 3.55. The company has a debt-to-equity ratio of 1.04, a quick ratio of 6.10 and a current ratio of 6.14. ASP Isotopes has a fifty-two week low of $3.92 and a fifty-two week high of $14.49.

Insider Buying and Selling

In other ASP Isotopes news, COO Robert Ainscow sold 8,438 shares of the firm’s stock in a transaction on Friday, March 6th. The shares were sold at an average price of $5.44, for a total value of $45,902.72. Following the completion of the transaction, the chief operating officer directly owned 1,537,817 shares of the company’s stock, valued at $8,365,724.48. This trade represents a 0.55% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 14.40% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ASP Isotopes

A number of institutional investors have recently made changes to their positions in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in ASP Isotopes by 9.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,613 shares of the company’s stock valued at $148,000 after acquiring an additional 2,709 shares during the period. Rhumbline Advisers increased its stake in ASP Isotopes by 20.9% in the 2nd quarter. Rhumbline Advisers now owns 78,994 shares of the company’s stock worth $581,000 after purchasing an additional 13,668 shares during the period. XTX Topco Ltd purchased a new position in ASP Isotopes in the 2nd quarter worth approximately $178,000. New York State Common Retirement Fund lifted its position in ASP Isotopes by 418.2% in the second quarter. New York State Common Retirement Fund now owns 17,100 shares of the company’s stock valued at $126,000 after purchasing an additional 13,800 shares during the last quarter. Finally, Invesco Ltd. lifted its position in ASP Isotopes by 2,205.0% in the second quarter. Invesco Ltd. now owns 471,219 shares of the company’s stock valued at $3,468,000 after purchasing an additional 450,776 shares during the last quarter. Hedge funds and other institutional investors own 16.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have recently commented on ASPI. Weiss Ratings restated a “sell (d-)” rating on shares of ASP Isotopes in a report on Monday, December 29th. Cantor Fitzgerald began coverage on ASP Isotopes in a report on Thursday, December 4th. They issued an “overweight” rating and a $13.00 target price on the stock. Two investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $13.00.

ASP Isotopes Company Profile

ASP Isotopes Inc, a development stage advanced materials company, focuses on the production, distribution, marketing, and sale of isotopes. It engages in the production and commercialization of Molybdenum-100, a non-radioactive isotope for the medical industry; Carbon-14; and Silicon-28. The company is also developing Quantum Enrichment technology to produce Ytterbium-176, Nickel-64, Lithium 6, Lithium7, and Uranium-235. ASP Isotopes Inc was incorporated in 2021 and is headquartered in Washington, District Of Columbia.